StockNews.AI
REGN
StockNews.AI
56 days

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

1. Regeneron launches a $200 million donation matching program for retinal disease. 2. Initiative enhances patient access to vital medications without incentivizing specific products. 3. Regeneron reinforces its commitment to social responsibility through philanthropy. 4. The program aims to support patients needing copay assistance for FDA-approved therapies. 5. Regeneron has donated over $2.5 billion to patient support organizations in the past decade.

12m saved
Insight
Article

FAQ

Why Bullish?

This initiative may improve Regeneron’s public image and increase medicine accessibility, likely boosting sales. Historical evidence shows that similar philanthropic efforts positively impact stock performance in biotech.

How important is it?

The program signifies Regeneron's commitment to corporate social responsibility and can enhance brand loyalty, indirectly influencing sales and stock value positively. A healthy public perception can lead to increased trust and long-term investor confidence.

Why Long Term?

The lasting reputation benefit and improved patient access can manifest over time, influencing long-term investor sentiment. Previous initiatives that focused on patient welfare have resulted in sustainable market awareness and loyalty.

Related Companies

BMYSNYAMGN
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications June 24, 2025 07:30 ET  | Source: Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days’ Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. “We are proud to support Good Days with this unprecedented philanthropic effort,” said Leonard Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. “By matching and thus doubling donations to Good Days’ Retinal Vascular and Neovascular Disease Fund, Regeneron can continue our longstanding support of patients through non-profit organizations, while encouraging others to join us in ensuring that even more patients can access the life-changing medicines they require to protect, restore and save their vision.” The Fund offers copay assistance to U.S. patients who meet certain criteria as determined by Good Days. Donations are never intended to incentivize usage of any particular product, and this copay support is given without regard to what medicine patients are prescribed, as long as the medicine is FDA-approved to treat their covered diagnosis. The donation matching program is part of Regeneron's broader commitment to improving patient outcomes and supporting healthcare access. Regeneron also facilitates access to medicines through product support and Managed Access Programs, patient assistance programs, and collaborations with experienced stakeholders, including nongovernmental organizations and public health agencies. Regeneron remains committed to supporting patient access to medications and believes that patients should be able to access whatever therapy their physician prescribes for them. In the past decade, Regeneron has donated over $2.5 billion dollars to independent charitable organizations that provide financial support to patients. Regeneron will match aggregated donations without receiving donor information; please contact Good Days directly to donate or for more information at: donations@mygooddays.org. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious disease, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF). For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. Forward-Looking Statements and Use of Digital MediaThis press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the availability and extent of reimbursement or copay assistance for products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) from third-party payors and other third parties, including Good Days and Good Days’ Retinal Vascular and Neovascular Disease Fund as discussed in this press release, as well as private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties, including the matching program for donations to Good Days to support Good Days’ Retinal Vascular and Neovascular Disease Fund as discussed in this press release; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) (including biosimilar versions of Regeneron’s Products); the nature, timing, and possible success and therapeutic applications of Regeneron’s Products and Regeneron’s Product Candidates and research and clinical programs now underway or planned; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Related News